Latest Press Releases
Sep 6, 2018 • 7:00am EDT
Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C
-- Co-funded Research to be Led by Dr. Mark Pimentel's Lab to Further Evaluate the Efficacy and Safety of SYN-010 in a 12-Week, Placebo-Controlled, Phase 2 Clinical Study -- ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has entered into an agreement with Cedars-Sinai Medical Center for an investigator-sponsored Phase 2 clinical study of SYN-010. The study will provide further evaluation of the efficacy and safety of SYN-010, the Company's modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company ...